PIKFYVE and amyotrophic lateral sclerosis: PIKfyve is a drug target for a variety of diseases, in particular SARS‐CoV‐2 infection.[10b, 11] Apilimod is a selective PIKfyve inhibitor under clinical evaluation against SARS‐CoV‐2 and ALS, but this compound has a fairly low bioavailability which may account for the low efficacy in prior clinical trials.[23] As 6 targets the lipid substrate binding site, we next examined whether its inhibitory effect can be combined with Apilimod which is known to target the ATP binding site (Figure S8).